Evidence map›Paper›PMID 42478844›Full record

ArticlemBio2026

Lanosterol synthase inhibition as a potential approach for re-sensitizing triazole-resistant

Jinhong Xie, Xabier Guruceaga, Adela Martin-Vicente, Harrison I Thorn, Devi Bale, Uxue Perez Cuesta, Asmita Nandi, Chendo Dieleman, Josie E Parker, Steven L Kelly and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in mBio, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Jinhong XieGraduate Program in Pharmaceutical Sciences, College of Graduate Health Sciences, University of Tennessee Health Science Center, Memphis, Tennessee, USA.
Xabier GuruceagaInstitute for Multidisciplinary Research in Applied Biology, Public University of Navarre, Pamplona, Spain.
Adela Martin-VicenteDepartment of Clinical Pharmacy and Translational Science, College of Pharmacy, University of Tennessee Health Science Center, Memphis, Tennessee, USA.ORCID 0000-0003-0446-8906
Harrison I ThornGraduate Program in Pharmaceutical Sciences, College of Graduate Health Sciences, University of Tennessee Health Science Center, Memphis, Tennessee, USA.
Devi BaleGraduate Program in Pharmaceutical Sciences, College of Graduate Health Sciences, University of Tennessee Health Science Center, Memphis, Tennessee, USA.
Uxue Perez CuestaDepartment of Clinical Pharmacy and Translational Science, College of Pharmacy, University of Tennessee Health Science Center, Memphis, Tennessee, USA.
Asmita NandiDepartment of Clinical Pharmacy and Translational Science, College of Pharmacy, University of Tennessee Health Science Center, Memphis, Tennessee, USA.
Chendo DielemanInstitute of Molecular Biology, BiocenteR, Medical University of Innsbruck, Innsbruck, Austria.
Josie E ParkerMolecular Biosciences Division, School of Biosciences, Cardiff University, Cardiff, Wales, United Kingdom.ORCID 0000-0002-3855-4194
Steven L KellyInstitute of Life Science, Swansea University Medical School, Swansea, Wales, United Kingdom.ORCID 0000-0001-7991-5040
Christoph MüllerDepartemnt of Pharmacy, Center for Drug Research, Ludwig-Maximilians-Universität München, Munich, Germany.
Fabio GsallerInstitute of Molecular Biology, BiocenteR, Medical University of Innsbruck, Innsbruck, Austria.ORCID 0000-0002-9257-8648
Jarrod R FortwendelDepartment of Clinical Pharmacy and Translational Science, College of Pharmacy, University of Tennessee Health Science Center, Memphis, Tennessee, USA.ORCID 0000-0003-2301-4272

Funding

Non-cyp51A-mutation Mediated Triazole Resistance in Aspergillus fumigatusR01AI143197 · NIAID · UNIVERSITY OF TENNESSEE HEALTH SCI CTR · PI FORTWENDEL, JARROD R., ROGERS, P. DAVID · 2020 to 2024
$3.3M
Austrian Science Fund DOI: 10.55776/P35951National Institute of Allergy and Infectious Diseases R01AI143197NIAID NIH HHS R01 AI143197
6 · The paper itself

Abstract

The increasing prevalence of triazole resistance among

Indexed as

Antifungal AgentsAspergillus fumigatusDrug Resistance, FungalEnzyme InhibitorsIntramolecular TransferasesTriazolesErgosterolFungal ProteinsHumansLanosterolMicrobial Sensitivity TestsAntifungal AgentsEnzyme InhibitorsErgosterolFungal ProteinsIntramolecular TransferasesLanosterollanosterol synthaseTriazolesantifungal resistanceAspergillus fumigatuserg7ergosterollanosterol synthasetriazole

Identifiers

PMID42478844
PMCPMC13463776

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.